Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Intravenous Stopcock Market to Surpass US$ 570.4 Million globally by end of 2027, Says CMI
12:00am, Friday, 03'rd Jul 2020
North America region is projected to be the most lucrative region in intravenous stopcock market, owing to the rising prevalence of chronic diseases.
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Pfizer (NYSE: PFE) - Markets
03:52pm, Thursday, 02'nd Jul 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX
Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes
11:30am, Thursday, 02'nd Jul 2020
Pacira BioSciences, Inc. (PCRX), a leading provider of innovative non-opioid pain management options, today announced that the company has notified DePuy Synthes Sales Inc. that the agreement between
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 1)
AbbVie Inc (NYSE: ABBV)
ADC...
The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes
12:00am, Wednesday, 01'st Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 30)
ADC Therapeutics SA (NYSE:...
Pacira Biosciences (NASDAQ:PCRX) Trading Up 0.6% Following Analyst Upgrade
01:26pm, Tuesday, 30'th Jun 2020
Pacira Biosciences Inc (NASDAQ:PCRX) shares were up 0.6% during trading on Tuesday after SVB Leerink raised their price target on the stock from $45.00 to $58.00. SVB Leerink currently has an outperfo
Northland Securities Maintains a Buy Rating on Verrica Pharmaceuticals (VRCA) - Markets
11:49am, Tuesday, 30'th Jun 2020
Northland Securities analyst Tim Chiang maintained a Buy rating on Verrica Pharmaceuticals (VRCA – Research Report) today and set a
Key Companies Profiled are MIRA Rehab Limited, Jintronix., Doctor On Demand, Inc., Care Innovations, LLC., American Well, NeoRehab, Hinge Health, Inc., Koninklijke Philips N.V. and other key market pl
Why Pacira BioSciences Is Soaring Today | The Motley Fool
04:58pm, Monday, 29'th Jun 2020
Thanks to a recent FDA decision, its best-selling product, Exparel, will go at least a little longer without facing competition from Heron Therapeutics' HTX-011.
Heron Therapeutics (HRTX) Initiated with a Buy at Stifel Nicolaus - Markets
03:44pm, Monday, 29'th Jun 2020
Stifel Nicolaus analyst Derek Archila initiated coverage with a Buy rating on Heron Therapeutics (HRTX – Research Report) today and
U.S. FDA again declines to approve Heron Therapeutics' non-opioid painkiller
02:04pm, Monday, 29'th Jun 2020
Heron Therapeutics said on Monday the U.S. Food and Drug Administration has once again declined to approve its non-opioid painkiller for post-operative pain and sought more data, sending its shares do
U.S. FDA seeks more data on Heron Therapeutics' non-opioid painkiller
01:00pm, Monday, 29'th Jun 2020Pacira Biosciences (NASDAQ:PCRX) Sets New 1-Year High at $52.32
11:10am, Monday, 29'th Jun 2020
Pacira Biosciences Inc (NASDAQ:PCRX)’s stock price hit a new 52-week high on Monday . The company traded as high as $52.32 and last traded at $51.90, with a volume of 565611 shares traded. The stock
Stifel Nicolaus Believes Momenta Pharma (NASDAQ: MNTA) Won't Stop Here - Markets
09:09pm, Wednesday, 24'th Jun 2020
Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Momenta Pharma (MNTA – Research Report) today. The company’s shares
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (NASDAQ: KPTI) and Pfizer (NYSE: PFE) - Markets
10:27am, Tuesday, 23'rd Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics
